Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a rare Q3 revenue miss and cut second half of the year guide on several factors impacting Cologuard. 2027 LRP targets are intact and Wells thinks growth will accelerate in 2025. The firm sees valuation support in low-$50s and views the 30% selloff as overdone.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
- Exact Sciences price target lowered to $65 from $82 at Craig-Hallum
- Exact Sciences price target raised to $85 from $84 at Jefferies
- Exact Sciences price target lowered to $60 from $80 at Evercore ISI